Skip to content

Effect of Zincovit ACTIVE Instant Rehydration Solution in fatigue and stress

A Prospective Comparative Placebo controlled clinical study to evaluate the efficacy and safety of Zincovit ACTIVE Instant Rehydration Solution in Fatigue/Stress - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067877
Enrollment
80
Registered
2024-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R538- Other malaise and fatigue

Interventions

Intervention1: Zincovit ACTIVE Instant Rehydration Solution: Zinc 1 mg, Potassium chloride 0.157 mg, Sodium citrate 0.294 mg, Magnesium 10 mg, Calcium 15 mg , Taurine 80 mg in Apple flavour/ Orange fl

Sponsors

Apex Laboratories Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Subjects, aged 18 years and above. 2) Subjects suffering from fatigue due to fever, post operative period, dehydration and tiredness after excessive physical activity. 3) Measurable fatigue, defined as a score of � 10 on the fatigue severity scale

Exclusion criteria

Exclusion criteria: 1) Severe dehydration and/or use of IV fluids for current hospitalization 2) Experiencing bloody diarrhea or diarrhea due to cholera, dysentery, persistent/chronic diarrhea, diarrhea with severe malnutrition, diarrhea associated with recent antibiotic use 3) In the opinion of the investigator, not suitable for treatment with IRS 4) Have any underlying disease or disorder that may, in the opinion of the investigator, affect the results of the study if they were enrolled (includes, but is not limited to, renal disease, gastrointestinal disorders such as Crohn's disease or other inflammatory bowel disease or congenital malabsorption disorders) 5)Known to be allergic to any of the components of the investigational product 6)Pregnant or lactating Women 7)Uncontrolled type 2 Diabetes mellitus (HbA1c>10). 8)A history of neurological or psychiatric diseases 9)Alcohol or substance abuse 10)Subjects taking any nutritional supplements.

Design outcomes

Primary

MeasureTime frame
1. Acute treatment effects on subjective arousal/stress/fatigue ratings as assessed by visual analogue scales during follow ups 2. Subjective ratings of arousal (concentration, mental stamina/physical stamina) stress and fatigue (mentally tired/physically tired) visual analogue scales 3. Changes in the electrolyte levels 4. Reduction in overall fatigue as measured by Fatigue Severity Scale 5. Convalescence time and cognitive assessment will be done 6. Study IRS intakeTimepoint: Baseline, 24 hrs, 48 hrs and 7 days

Secondary

MeasureTime frame
1. Study Subject & investigator feedbacks & quality of life will be assessed 2. Medically confirmed adverse events collected throughout the study period 3. Record study subject use of antibiotics & other drugs during hospitalizationTimepoint: Baseline, 24 hrs, 48 hrs & 7 days

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

Ki3 Private Limited

saheerose@gmail.com9443627722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 27, 2026